Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
450 patients around the world
Available in Argentina
GlaxoSmithKline
450Patients around the world
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Participants who have previously received at least one dose of GSK3228836 and Achieved SVR (defined as HBsAg and HBV DNA < lower limit of quantification (LLOQ) from end of previous investigational treatment until the End of study (EoS) visit in the previous treatment study (complete responder) OR Participants who have previously received at least one dose of GSK3228836 and demonstrated a partial response to GSK3228836 in the previous treatment study Participants who enter the study on stable NA must be willing to discontinue NA treatment in accordance with the NA discontinuation schedule. Capable of giving signed informed consent.
Participants who have/or are currently participating in another non-GSK interventional clinical study exploring HBV treatment since completing their treatment with GSK3228836. Any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.
